During the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub spoke to María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, about which patients would be ideal candidates to be included in a clinical trial for smoldering myeloma.
Which patients with smoldering multiple myeloma would you enrol in a clinical trial?
María-Victoria Mateos discusses the importance of stratifying patients with smoldering multiple myeloma (MM) according to the risk of progression to MM, before enrolling them in clinical trials. The ideal candidates for inclusion in clinical trials for smoldering MM are patients at high risk of developing MM, in which the progression risk to MM is 50% at two years, and who would benefit more from treatment.
Subscribe to get the best content related to multiple myeloma delivered to your inbox every month
